AbbVie Inc. Non-operating Income/Expense

Non-operating Income/Expense of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-operating Income/Expense growth rates and interactive chart. Income or expense that is usually non-recurring and not tied to a company's operations. It is stated separately on the income statement to differentiate it from operating expenses.


Highlights and Quick Summary

  • Non-operating Income/Expense for the quarter ending September 29, 2021 was $265 Million (a -83.72% decrease compared to previous quarter)
  • Year-over-year quarterly Non-operating Income/Expense decreased by -95.16%
  • Annual Non-operating Income/Expense for 2020 was $10.1 Billion (a 123.62% increase from previous year)
  • Annual Non-operating Income/Expense for 2019 was $4.51 Billion (a -15.29% decrease from previous year)
  • Annual Non-operating Income/Expense for 2018 was $5.32 Billion (a 182.39% increase from previous year)
  • Twelve month Non-operating Income/Expense ending September 29, 2021 was $7.36 Billion (a -3.2% decrease compared to previous quarter)
  • Twelve month trailing Non-operating Income/Expense increased by 82.29% year-over-year
Trailing Non-operating Income/Expense for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$7.36 Billion $7.6 Billion $4.53 Billion $4.04 Billion
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-operating Income/Expense of AbbVie Inc.

Most recent Non-operating Income/Expenseof ABBV including historical data for past 10 years.

Interactive Chart of Non-operating Income/Expense of AbbVie Inc.

AbbVie Inc. Non-operating Income/Expense for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $265.0 $1,628.0 $-12.0
2020 $5,480.0 $508.0 $-1,445.0 $-505.0 $10,083.0
2019 $-882.0 $-616.0 $-2,593.0 $-466.0 $4,509.0
2018 $68.0 $-398.0 $-750.0 $-106.0 $5,323.0
2017 $-589.0 $-599.0 $-309.0 $-321.0 $1,885.0
2016 $-316.0 $-347.0 $-291.0 $-502.0 $423.0
2015 $-189.0 $-238.0 $-174.0 $-291.0 $-892.0
2014 $-622.0 $-273.0 $-82.0 $-65.0 $-1,042.0
2013 $-96.0 $-85.0 $-85.0 $-66.0 $-332.0
2012 $-108.0 $8.0 $-20.0 $28.0 $-92.0
2011 $14.12 $33.89 $48.0
2010 $119.0

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.